NEXT-GENERATION NK CELL-BASED IMMUNOTHERAPIES FOR HARD-TO-TREAT CANCERS
Associate Professor Fernando S. F. Guimaraes, PhD, GAICD
Group Leader, Translational Innate Immunotherapy
Frazer Institute, Faculty of Medicine,
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | February 2025
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
A/Prof Guimaraes completed his PhD at the Institut Pasteur and pursued postdoctoral research at QIMR Berghofer and WEHI before joining UQ in 2019. His pioneering work has significantly advanced understanding of immune evasion mechanisms in cancer, leading to potential breakthroughs in NK cell therapies. His research integrates systems biology, experimental oncology, and bioinformatics to design novel, targeted treatments resistant to tumour-induced immunosuppression. His contributions have earned him numerous awards, including the QLD Tall Poppy, UQ Frazer Institute Rising Star, Translational Research Institute – Connecting with the Clinic Awards.
He has published extensively in top-tier journals, secured and led major research funding (NHMRC, MRFF, US DoD) focused on NK cell therapies. A/Prof Guimaraes also plays a key role in mentoring early-career researchers, serving as the Chair of the Research Committee at Cure Cancer Australia and leading multiple international collaborations.
Source: supplied
https://orcid.org/0000-0002-2037-8946
-
Professor Matthew Kiernan
BRAIN AND MIND CENTRE
@ UNIVERSITY OF SYDNEY, NEW SOUTH WALES AUSTRALIA -
Cellular interactions responsible for development, maintenance, and strength of the skeleton
Professor Sims directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute of Medical Research and is a Professorial Fellow at The University of Melbourne and Australian Catholic University.
She leads a team who studies the cellular interactions responsible for development, maintenance, and strength of the skeleton. She completed her PhD at the University of Adelaide, followed by postdoctoral work at the Garvan Institute in Sydney then at Yale School of Medicine, in New Haven, Connecticut, where she studied the role of the estrogen receptor in regulating bone structure.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
